In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking ...
Summit and Akeso's ivonescimab attracted headlines earlier this year when it was shown to be more effective than anti-PD-1 ...
For patients with obesity and prediabetes, three years of tirzepatide yields substantial and sustained weight reductio ...
Medpage Today on MSN1d
Tirzepatide Officially Puts GLP-1 Meds on the Map for Obesity-Related Heart FailureCHICAGO -- A long-acting GIP/GLP-1 receptor agonist conferred significant clinical benefit for people with obesity and ...
Payers and employers have tightened access to the glucagon-like peptide-1 receptor agonist class once these therapies became ...
Pharmacies that make customized medications are asking the federal Food and Drug Administration to protect their right to ...
Spanning 176 weeks of treatment, the Phase III trial evaluated the efficacy and safety of tirzepatide in adults without type ...
The detailed results were published in The New England Journal of Medicine and were presented at ObesityWeek 2024.
In a phase-3 randomized controlled trial published in the New England Journal of Medicine, researchers investigated the effects of tirzepatide on weight reduction and diabetes prevention in ...
Results from a retrospective cohort study show lower all-cause mortality and fewer hospitalizations and intestinal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback